PFE and BMY undoubtedly.
The worst is LLY. Then comes BMY. LLY has four of its five largest products losing patent protection between late 2011 and 2013 and they haven't done a thing about it. And because of that, analysts on balance see 2011 EPS of $4.47 plunging all the way down to $3.12 three years later. The $3.12 for 2014 isn't THAT much more than the $2.34 expected for Pfizer and yet LLY sells for $35.60 while PFE languishes at $15.00.Just what makes LLY worth paying $35.60 for?If LLY deserves to be $35.60 right now, PFE should be $25. And if $15 is fair for Pfizer right now, LLY shouldn't be more than low-20's.